Sutro Biopharma Inc
STRO0.806USD
-0.004-0.48%
시장 운영 시간 （ET）시세는 15분 지연됩니다
67.99M시가총액
손실P/E TTM
자세한 내용은 Sutro Biopharma Inc 회사
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
회사 정보
종목 코드 STRO
회사 이름Sutro Biopharma Inc
상장일Sep 27, 2018
CEOMs. Jane Chung
직원 수310
유형Ordinary Share
회계 연도 종료Sep 27
주소111 Oyster Point Blvd.
도시SOUTH SAN FRANCISCO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호94080
전화16503928412
웹사이트https://www.sutrobio.com/
종목 코드 STRO
상장일Sep 27, 2018
CEOMs. Jane Chung
회사 임원
이름
이름/직위
직위
주식 보유
변동
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
116.24K
--
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
53.69K
+3.08%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Mr. Joseph M. Lobacki
Mr. Joseph M. Lobacki
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Panek
Mr. James P. (Jim) Panek
Independent Director
Independent Director
--
--
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
--
--
Ms. Emily White
Ms. Emily White
Executive Director - Investor Relations and Communications
Executive Director - Investor Relations and Communications
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
116.24K
--
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
53.69K
+3.08%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 17
마지막 업데이트: Sat, May 17
주주
주주 유형
주주
주주
비율
Suvretta Capital Management, LLC
8.84%
BlackRock Institutional Trust Company, N.A.
6.59%
Kynam Capital Management LP
6.44%
Millennium Management LLC
5.59%
RA Capital Management, LP
5.25%
Other
67.30%
주주
주주
비율
Suvretta Capital Management, LLC
8.84%
BlackRock Institutional Trust Company, N.A.
6.59%
Kynam Capital Management LP
6.44%
Millennium Management LLC
5.59%
RA Capital Management, LP
5.25%
Other
67.30%
주주 유형
주주
비율
Hedge Fund
29.69%
Investment Advisor/Hedge Fund
18.32%
Investment Advisor
17.28%
Venture Capital
8.09%
Corporation
3.22%
Research Firm
1.44%
Individual Investor
1.37%
Pension Fund
0.34%
Bank and Trust
0.11%
Other
20.12%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
291
67.18M
79.53%
-15.59M
2025Q1
295
63.49M
75.19%
-18.52M
2024Q4
299
65.68M
79.84%
-13.78M
2024Q3
295
64.44M
78.61%
-17.80M
2024Q2
286
64.98M
79.66%
-15.82M
2024Q1
291
55.64M
88.75%
-15.66M
2023Q4
302
58.38M
95.62%
-12.57M
2023Q3
306
61.36M
101.61%
-9.98M
2023Q2
312
60.26M
100.55%
-11.07M
2023Q1
320
58.55M
98.20%
-11.55M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Suvretta Capital Management, LLC
7.46M
8.84%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.57M
6.59%
-721.98K
-11.48%
Mar 31, 2025
Kynam Capital Management LP
5.44M
6.44%
+1.80M
+49.43%
Mar 31, 2025
Millennium Management LLC
4.72M
5.59%
+4.01M
+570.86%
Jun 27, 2025
RA Capital Management, LP
4.43M
5.25%
+4.43M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.40M
5.2%
+186.74K
+4.44%
Mar 31, 2025
Acadian Asset Management LLC
3.13M
3.71%
+1.38M
+78.92%
Mar 31, 2025
Merck & Co Inc
2.72M
3.22%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.60M
3.08%
+30.00K
+1.17%
Mar 31, 2025
Eversept Partners, LP
2.29M
2.71%
+1.60M
+230.10%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares US Small-Cap Equity Factor ETF
0%
Global X Russell 2000 Covered Call ETF
0%
더 보기
Vanguard US Value Factor ETF
비율0.02%
ProShares Ultra Nasdaq Biotechnology
비율0.01%
iShares Micro-Cap ETF
비율0.01%
Invesco Nasdaq Biotechnology ETF
비율0.01%
iShares Biotechnology ETF
비율0.01%
Global X Russell 2000 ETF
비율0%
iShares Russell 2000 ETF
비율0%
ProShares UltraPro Russell2000
비율0%
iShares US Small-Cap Equity Factor ETF
비율0%
Global X Russell 2000 Covered Call ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
